Chengdu Easton Biopharmaceuticals Co., Ltd.SSE: 688513

Report for Q3 2025

Oct 28, 2025 · Issued by Chengdu Easton Biopharmaceuticals Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Oct 28, 2025

On 6ix: 6ix.com/news/report-for-q3-2025-724

Report for Q3 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Chengdu Easton Biopharmaceuticals Co., Ltd. on 6ix

Earlier from Chengdu Easton Biopharmaceuticals

Announcement on Convening the Q3 2025 Performance BriefingOct 24, 2025
Announcement on Voluntary Disclosure of Iguratimod Tablets Obtaining Drug Registration CertificateOct 18, 2025
Announcement on New Recognized Core Technical PersonnelOct 14, 2025
Announcement on Progress in Capital Increase in Joint-stock Company and Related Party TransactionsOct 11, 2025
Announcement on Election of Employee Representative Directors for the 4th Board of DirectorsOct 10, 2025

Later from Chengdu Easton Biopharmaceuticals

Announcement on Voluntary Disclosure of Prospective Winning in the National Centralized Drug ProcurementOct 29, 2025
Announcement on Progress in Completion of Capital Increase to Joint-stock Company and Related Party TransactionsNov 5, 2025
Announcement on Voluntary Disclosure of the Initiation of Phase I/II Clinical Trial for YLSH003 for Injection and Completion of the 1st Subject EnrollmentNov 11, 2025
Announcement on Voluntary Disclosure of Wholly-owned Subsidiary Chengdu Shuode Pharmaceutical Passing U.S. FDA On-site InspectionNov 28, 2025
Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Brexpiprazole TabletsDec 10, 2025

All Chengdu Easton Biopharmaceuticals news releases

Follow Chengdu Easton Biopharmaceuticals into a list and get an email when it puts out news.

Follow Chengdu Easton Biopharmaceuticals